CL2017001457A1 - Régimen de dosificación para un agonista selectivo del receptor s1p1. - Google Patents
Régimen de dosificación para un agonista selectivo del receptor s1p1.Info
- Publication number
- CL2017001457A1 CL2017001457A1 CL2017001457A CL2017001457A CL2017001457A1 CL 2017001457 A1 CL2017001457 A1 CL 2017001457A1 CL 2017001457 A CL2017001457 A CL 2017001457A CL 2017001457 A CL2017001457 A CL 2017001457A CL 2017001457 A1 CL2017001457 A1 CL 2017001457A1
- Authority
- CL
- Chile
- Prior art keywords
- selective
- receptor agonist
- dosing regimen
- propilimino
- tiazolidin
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE RELACIONA CON UN RÉGIMEN DE DOSIFICACIÓN PARA (R)-5-[3-CLORO-4-(2,3-DIHIDROXI-PROPOXI)-BENZ[Z]ILIDEN]-2-([Z]PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2014077469 | 2014-12-11 | ||
EP2015058202 | 2015-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017001457A1 true CL2017001457A1 (es) | 2018-02-09 |
Family
ID=54843844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001457A CL2017001457A1 (es) | 2014-12-11 | 2017-06-08 | Régimen de dosificación para un agonista selectivo del receptor s1p1. |
Country Status (31)
Country | Link |
---|---|
US (4) | US10220023B2 (es) |
EP (2) | EP4056179A1 (es) |
JP (1) | JP6244497B1 (es) |
KR (4) | KR20200013086A (es) |
CN (2) | CN106999461A (es) |
AU (2) | AU2015359346B2 (es) |
CA (1) | CA2968180C (es) |
CL (1) | CL2017001457A1 (es) |
CY (1) | CY1125170T1 (es) |
DK (1) | DK3256125T3 (es) |
EA (1) | EA036075B1 (es) |
ES (1) | ES2909071T3 (es) |
FR (1) | FR22C1021I2 (es) |
HR (1) | HRP20220359T8 (es) |
HU (2) | HUE057865T2 (es) |
IL (1) | IL252727B (es) |
LT (2) | LT3256125T (es) |
MX (2) | MX2017007638A (es) |
MY (1) | MY188764A (es) |
NL (1) | NL301174I2 (es) |
NO (1) | NO2022023I1 (es) |
PH (1) | PH12017501059A1 (es) |
PL (1) | PL3256125T3 (es) |
PT (1) | PT3256125T (es) |
RS (1) | RS63048B1 (es) |
SG (1) | SG11201704563RA (es) |
SI (1) | SI3256125T1 (es) |
TW (1) | TW201625242A (es) |
UA (1) | UA122064C2 (es) |
WO (1) | WO2016091996A1 (es) |
ZA (1) | ZA201704624B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR20200013086A (ko) | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
EP4003338A1 (en) | 2019-07-22 | 2022-06-01 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
JP2023501217A (ja) | 2019-10-31 | 2023-01-18 | イドーシア ファーマシューティカルズ リミテッド | Cxcr7アンタゴニストのs1p1受容体調節剤との合剤 |
TW202146015A (zh) | 2020-03-06 | 2021-12-16 | 瑞士商艾克泰聯製藥有限公司 | 減緩腦體積損失之方法 |
CA3213818A1 (en) | 2021-03-17 | 2022-09-22 | Actelion Pharmaceuticals Ltd | Pharmaceutical dosage system |
WO2023062511A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
CA3220684A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
CA3220715A1 (en) | 2021-10-11 | 2023-04-20 | Krista Spiller | Methods of treating multiple sclerosis |
US20230144895A1 (en) | 2021-10-11 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods Of Treating Multiple Sclerosis |
WO2023079079A1 (en) | 2021-11-05 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods for treating multiple sclerosis |
WO2023152290A1 (en) | 2022-02-11 | 2023-08-17 | Actelion Pharmaceuticals Ltd | Methods of slowing an increase in brain ventricular volume |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
EP2295418A1 (en) | 2003-11-21 | 2011-03-16 | Actelion Pharmaceuticals Ltd. | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
AU2005309378B2 (en) | 2004-11-29 | 2010-02-11 | Novartis Ag | Dosage regimen of an S1P receptor agonist |
US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
CN103087004A (zh) | 2006-11-23 | 2013-05-08 | 埃科特莱茵药品有限公司 | 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法 |
KR101718639B1 (ko) * | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
EP2379067B1 (en) | 2008-12-22 | 2015-09-02 | Novartis AG | Dosage regimen for fingolimod for the treatment of multiple sclerosis |
BRPI0923213A2 (pt) | 2008-12-22 | 2016-01-26 | Novaris Ag | regime de dosagem de um agonista do receptor para s1p. |
CA2895172C (en) | 2012-08-17 | 2020-08-18 | Actelion Pharmaceuticals Ltd | Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process |
KR20200013086A (ko) * | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
-
2015
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Application Discontinuation
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/en active Pending
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Application Discontinuation
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 MX MX2017007638A patent/MX2017007638A/es unknown
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/en active Application Filing
- 2015-12-10 CA CA2968180A patent/CA2968180C/en active Active
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active IP Right Grant
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active IP Right Grant
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/en active Active
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
-
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
-
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
-
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
-
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-20 LT LTPA2022505C patent/LTPA2022505I1/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US20230131600A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001457A1 (es) | Régimen de dosificación para un agonista selectivo del receptor s1p1. | |
ECSP17044494A (es) | Receptores de antígenos quiméricos de bcma | |
DK3368060T3 (da) | Glugacon-receptor-agonister | |
DK3283110T3 (da) | Antistoffer rettet mod interleukin-36-receptor (il-36r) | |
MA41481B1 (fr) | Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif | |
DK3762380T3 (da) | Phenylpyrrolidinon-formylpeptid-2-receptoragonister | |
DK3325487T3 (da) | Formulering til bløde, anticholinerge analoger | |
CL2013003686A1 (es) | Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña. | |
MA43297A (fr) | Semelle, en particulier pour chaussures | |
MA40858A (fr) | Composés antagonistes des récepteurs d3 à la dopamine | |
DK3265459T3 (da) | Amidforbindelser som 5-ht4-receptoragonister | |
CL2018000489A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
DK3250549T3 (da) | Cyclopropylmethanaminer som selektive 5-HT(2C)-receptoragonister | |
GB201816746D0 (en) | Cyclic apelin receptor agonists | |
IT201700043199U1 (it) | Calzatura per cavalli | |
TH1601000316A (th) | อะโกนิสต์ของตัวรับวาโซเพรสซิน-2 | |
TH1401006488B (th) | เครื่องกลเพื่อการบรรจุแบบลูกสูบ | |
NO20141556A1 (no) | Stabiliseringsanordning for hundeskål, samt hundeskålsett |